Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Dig Dis ; 18(4): 203-206, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28371414

RESUMEN

It has been a great challenge for gastroenterologists to cope with functional gastrointestinal disorders (FGIDs) in clinical practice due to the contemporary increase in stressful events. A growing body of evidence has shown that neuroregulators such as anti-anxiety agents and antidepressants function well on FGIDs, particularly in cases that are refractory to classical gastrointestinal (GI) medications. Among these central-acting agents, small individualized doses of tricyclic antidepressants and selective serotonin reuptake inhibitors are usually recommended as a complement to routine GI management. When these drugs are chosen to treat FGIDs, both their central effects and the modulation of peripheral neurotransmitters should be taken into consideration. In this article we recommend strategies for choosing drugs based on an analysis of psychosomatic GI symptoms. The variety and dosage of the neurotransmitter regulators are also discussed.


Asunto(s)
Antidepresivos/uso terapéutico , Enfermedades Gastrointestinales/tratamiento farmacológico , Enfermedades Gastrointestinales/psicología , Neurotransmisores/fisiología , Trastornos Psicofisiológicos/tratamiento farmacológico , Disonancia Cognitiva , Enfermedades Gastrointestinales/etiología , Enfermedades Gastrointestinales/fisiopatología , Humanos , Trastornos Mentales/complicaciones , Trastornos Mentales/terapia , Trastornos del Humor/complicaciones , Trastornos del Humor/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA